Physician profile
Robert E Meeks
NPI 1134122385
$3,242.19
in general payments reported to CMS, 2019-2025
42 companies · $577 in 2025
The $577 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $265 · 2021: $572 · 2022: $706 · 2023: $383 · 2024: $345 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.55 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $430.06 | 2019-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $342.07 | 2022-2025 | Veozah |
| Abbvie INC. | $222.80 | 2019-2023 | |
| Coopersurgical, INC. | $180.76 | 2019-2025 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $179.82 | 2019-2025 | |
| Aspira Women'S Health INC | $146.32 | 2021-2024 | Ova1 |
| Daiichi Sankyo INC. | $116.26 | 2019-2023 | Injectafer |
| Hologic Sales and Service, LLC | $105.90 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $105.22 | 2025 | Gemtesa |
| Mayne Pharma Commercial LLC | $103.16 | 2022-2025 | |
| Organon LLC | $102.38 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $97.96 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $79.12 | 2021-2022 | |
| Pfizer INC. | $75.02 | 2021-2023 | |
| Exeltis, USA INC. | $74.20 | 2021-2025 | Slynd |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Meeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.